Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3984 The contribution of functional imaging in predicting the risk of recurrence after pancreatic surgery for neuroendocrine tumors

Introduction: Pancreatic neuroendocrine tumors (pNETs) are rare and heterogeneous, comprising 1 to 3% of all pancreatic neoplasms. The recurrence rate of non-metastatic pNETs varies, reaching up to 50% depending on the series, highlighting the difficulty in selecting candidates for surgery. However, there is no published data regarding the prognostic value of functional PET imaging combined with clinical and pathological characteristics.

Conference:

Presenting Author:

Authors: Pencréac'h S, de Mestier L, Fuks D, Paye F, de Ponthaud C,

Keywords: pNET, PET-68Ga-DOTATOC, recurrence, pancreatic surgery,

#2017 Data on Healthcare Resource Utilization (HCRU) and Treatment Modalities in Patients (Pts) with Advanced (adv), Well-Differentiated (WD) Neuroendocrine Tumors (NETs) of Gastrointestinal (GI) or Lung Origin in Finland

Introduction: The majority of all NETs develop in the GI tract and about one third develop in the lungs; approximately 43% and 51% of pts, respectively, are diagnosed with adv disease (regional or distant metastasis). While GI and lung NETs are rare, their incidence has increased markedly over the past four decades. The severe and progressive nature of adv NET suggests significant costs for pts and payers.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Gaasvik L, Aavikko M, Kurki S, Oddershede L,

Keywords: NET, HCRU, GI, Lung,

#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands

Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kansal A, Chao R, Patyna S, Scheijbeler H, Klok R,

Keywords: pancreatic NET, Sunitinib, overall survival, cost-effectiveness,